Navigation Links
Waters Publishes Rapid and Specific Method of Detection for Melamine in Infant Formula and Liquid Milk, in Support of China's Ministry of Science and Technology
Date:10/17/2008

MILFORD, Mass., Oct. 17 /PRNewswire-FirstCall/ -- Waters Corporation (NYSE: WAT) today published a rapid method for the detection of melamine in infant formula and liquid milk as outlined by requirements of China's Ministry of Science and Technology (M.O.S.T.). The new method uses Waters(R) ACQUITY(R) TQD, liquid chromatography combined with tandem quadrupole mass spectrometry (UPLC/MS/MS) operated in Multiple Reaction Monitoring (MRM) mode, and Waters MassLynx(TM) 4.1 Software with IntelliStart(TM) technology for data acquisition and MS parameters optimization.

Following an increased incidence of kidney stones and renal failure in infants in China believed to be associated with the ingestion of contaminated infant formula, M.O.S.T. issued guidelines for the development of melamine detection methods to be used throughout the nation. Specifically, M.O.S.T. is seeking accurate, reproducible detection of melamine of less than or equal to 2 mg/kg (ppm). Moreover, authorities in the US have declared that no tolerance can be set for the presence of melamine in infant formula. This indicates the need for an analytical method capable of accurately quantifying melamine across a wide range of concentrations.

Waters published method meets or exceeds these requirements. Specifically, Waters UPLC/MS/MS detection method can detect melamine contamination as low as 1 microgram/Kg (ppb) with an achievable sample throughput better than one sample every 15 minutes.

"Waters has a history of working with China's Ministry of Science and Technology by listening to their needs and providing solutions," said James Willis, Senior Director, Chemical Analysis Business for the Waters Division. "Analytical instrument companies in China are all providing training to assist food safety scientists throughout the nation. What is most important is that the foundation of this training is a scientifically sound, reproducible method that meets the requirements of China's highest scientific authorities for detection of melamine in milk and infant formula -- and that is what Waters has published today."

The rapid method for the screening and confirmation of melamine contamination in infant formula and liquid milk by UPLC/MS/MS, can be found on Waters' Website at: http://www.waters.com/waters/library.htm?locale=en_US&cid=514887&lid=10087429&xcid =91 86 (due to the length of the URL, please copy and paste into web browser).

About Waters Corporation (http://www.waters.com)

Waters Corporation creates business advantages for laboratory-dependent organizations by delivering practical and sustainable innovation to enable significant advancements in such areas as healthcare delivery, environmental management, food safety, and water quality worldwide.

Pioneering a connected portfolio of separations science, laboratory information management, mass spectrometry and thermal analysis, Waters technology breakthroughs and laboratory solutions provide an enduring platform for customer success.

With revenue of $1.47 billion in 2007 and 5,000 employees, Waters is driving scientific discovery and operational excellence for customers worldwide.

Waters, UltraPerformance LC, UPLC, ACQUITY UPLC, IntelliStart, MassLynx, and ACQUITY TQD are trademarks of Waters Corporation.

Media Contact

Brian J. Murphy

Public Relations

+1 508-482-2614

brian_j_murphy@waters.com


'/>"/>
SOURCE Waters Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Silver Lake Research Unveils Watersafe(R) Well Water Test Kit
2. Waters Brings Advanced Laboratory Data Management to Microsofts BioIT Alliance
3. David H. Murdock Research Institute Taps Waters for Laboratory Technology
4. Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
5. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
6. Consortium publishes Phase II map of human genetic variation
7. The Lancet Publishes Vasogens ACCLAIM Results
8. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
9. The Lancet Publishes Results From Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
10. Springer publishes anthology with the Nanoethics Group
11. The Scientific Business of Thomson Reuters Publishes Its 2008 Liquent Regulatory Affairs Trends Survey Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... BellBrook Labs ... to include an array of biochemical analyses critical for Lead Discovery. The ... hit-to-lead and SAR programs, including inhibitor potency and selectivity, mechanism of action, and ...
(Date:2/23/2017)... ATLANTA , Feb. 23, 2017  In Atlanta, it ... art, fashion, and culture intertwine to create an expressive and ... often reflect this energy and contribute to it. ... , Hair Fairies seeks to carry on that ... The Atlanta salon is the newest ...
(Date:2/23/2017)... ... February 23, 2017 , ... Brain Sentinel, Inc. has ... the SPEAC® System, the Brain Sentinel® Seizure Monitoring and Alerting System. The adjunctive ... during periods of rest. A lightweight, non-invasive monitor is placed on the belly ...
(Date:2/23/2017)... ... , ... Today, researchers can fast-track sample collection and analysis ... biomarkers or SNPs of interest) using one, easy-to-collect saliva sample. With the addition ... insulin and other relevant biomarkers can be extensively studied through a non-invasive sample ...
Breaking Biology Technology:
(Date:2/3/2017)... 3, 2017  Texas Biomedical Research Institute announced that its ... Schlesinger as the Institute,s new President and CEO. Dr. ... 31, 2017. He is currently the Chair of the Department ... for Microbial Interface Biology at Ohio State University. ... President and CEO of Texas Biomed," said Dr. James ...
(Date:2/2/2017)... 2, 2017   TapImmune, Inc. (NASDAQ: ... specializing in the development of innovative peptide and ... cancer and metastatic disease, announced today it has ... of a second clinical lot of TPIV 200, ... alpha. The manufactured vaccine product will be used ...
(Date:2/2/2017)... TOKYO , Feb. 1, 2017  Central ... innovative and meaningful advances worldwide, The Japan Prize ... Japan Prize, who have pushed the envelope in ... Information and Communication. Three scientists are being recognized ... outstanding achievements that not only contribute to the ...
Breaking Biology News(10 mins):